Loading clinical trials...
Loading clinical trials...
An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
Conditions
Interventions
RAP-219
Locations
7
United States
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho, United States
Mayo Clinic
Rochester, Minnesota, United States
NYU Langone Comprehensive Epilepsy Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Pennsylvania - Department of Neurology
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
December 15, 2025
Primary Completion Date
February 3, 2028
Completion Date
February 3, 2028
Last Updated
January 23, 2026
NCT02531880
NCT06097195
NCT06315322
NCT06388707
NCT07505004
NCT06794606
Lead Sponsor
Rapport Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions